A new drug developed by AstraZeneca has shown benefits in treating common types of breast cancer, sending shares in the FTSE 100 pharmaceuticals group up by 1.5 per cent.
Astra, led by Sir Pascal Soriot, said that a trial of datopotamab deruxtecan, known as Dato-DXd, showed “a statistically significant and clinically meaningful improvement” in slowing the progression of the cancer, compared with traditional chemotherapy. The trial also showed a “trend in improvement” in overall survival rates and will continue to assess this.
Astra shares suffered a sharp sell-off in July when it disappointed investors with the results of a trial of the same drug for treating lung cancer. Although that trial showed that Dato-DXd, jointly developed with Japan’s Daiichi Sankyo, slowed progression of the disease
© Times Media Limited 2023.
Registered in England No. 894646. Registered office: 1 London Bridge Street, SE1 9GF.